Cancer biotech Vivace Therapeutics is tuning up for a phase 3 trial after its potential first-in-class small molecule scored a 32% objective response rate in patients with treatment-resistant ...
PDS Biotech's Phase 2 study shows potential breakthrough in treating HPV16-positive head and neck cancer. The study shows a 87.1% 12-month survival rate for ICI naive patients, nearly doubling typical ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min This week's life sciences ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results